Hemostemix Announces the First Tranche Closing of $1.8M of Its Recently Announced Private Placement
Hemostemix has closed the first tranche of its private placement, raising $1.8 million through the issuance of 36.8 million Units at $0.05 per Unit. Each Unit includes one common share and one warrant exercisable at $0.12 for 24 months. The company paid finder fees of $88,660 and issued 1.7 million finder's options. Additionally, the company granted 3.7 million stock options to directors, officers, employees, and consultants at $0.10 per share, expiring October 31, 2029. The company will also issue 4.1 million shares at $0.10 per share to satisfy $408,547 in convertible debenture interest.
Hemostemix ha chiuso il primo tranche del suo collocamento privato, raccogliendo 1,8 milioni di dollari attraverso l'emissione di 36,8 milioni di unità a $0,05 per unità. Ogni unità include una azione comune e un warrant esercitabile a $0,12 per 24 mesi. L'azienda ha pagato commissioni ai procuratori di $88.660 e ha emesso 1,7 milioni di opzioni per i procuratori. Inoltre, l'azienda ha concesso 3,7 milioni di stock options a direttori, funzionari, dipendenti e consulenti a $0,10 per azione, con scadenza il 31 ottobre 2029. L'azienda emetterà anche 4,1 milioni di azioni a $0,10 per azione per soddisfare $408.547 in interessi su obbligazioni convertibili.
Hemostemix ha cerrado la primera tranche de su colocación privada, recaudando $1.8 millones a través de la emisión de 36.8 millones de Unidades a $0.05 por Unidad. Cada Unidad incluye una acción ordinaria y una opción de compra ejercitable a $0.12 durante 24 meses. La empresa pagó comisiones de búsqueda de $88,660 y emitió 1.7 millones de opciones de búsqueda. Además, la empresa concedió 3.7 millones de opciones sobre acciones a directores, funcionarios, empleados y consultores a $0.10 por acción, que vencerán el 31 de octubre de 2029. La empresa también emitirá 4.1 millones de acciones a $0.10 por acción para satisfacer $408,547 en intereses de bonos convertibles.
헤모스템믹스는 사모 모집의 첫 번째 트랜치를 마감하고 180만 달러를 모금했습니다. 이는 유닛 36.8백만 개를 유닛당 $0.05에 발행한 것입니다. 각 유닛은 한 주식과 24개월 동안 $0.12에 행사할 수 있는 워런트를 포함합니다. 회사는 찾아준 사람에게 $88,660의 수수료를 지불했으며 170만 개의 찾기 옵션을 발행했습니다. 또한, 회사는 이사, 임원, 직원 및 컨설턴트에게 주당 $0.10에 대해 370만 개의 주식 옵션을 부여했습니다. 이 옵션은 2029년 10월 31일에 만료됩니다. 회사는 또한 전환 사채 이자 $408,547를 충족하기 위해 주당 $0.10에 410만 주를 발행할 것입니다.
Hemostemix a clôturé la première tranche de son placement privé, levant 1,8 million de dollars par l'émission de 36,8 millions d'unités à 0,05 dollar par unité. Chaque unité comprend une action ordinaire et un bon de souscription exerçable à 0,12 dollar pendant 24 mois. L'entreprise a payé des frais de recherche s'élevant à 88 660 dollars et a émis 1,7 million d'options de recherche. De plus, l'entreprise a attribué 3,7 millions d'options d'achat d'actions aux directeurs, dirigeants, employés et consultants à 0,10 dollar par action, expirant le 31 octobre 2029. L'entreprise émettra également 4,1 millions d'actions à 0,10 dollar par action pour satisfaire 408 547 dollars d'intérêts sur des obligations convertibles.
Hemostemix hat die erste Tranche seiner Privatplatzierung abgeschlossen und 1,8 Millionen Dollar durch die Emission von 36,8 Millionen Einheiten zu je 0,05 Dollar pro Einheit gesammelt. Jede Einheit umfasst eine Stammaktie und ein für 24 Monate zu 0,12 Dollar ausübbares Warrant. Das Unternehmen zahlte Vermittlungsgebühren in Höhe von 88.660 Dollar und stellte 1,7 Millionen Vermittlungsoptionen aus. Darüber hinaus gewährte das Unternehmen 3,7 Millionen Aktienoptionen an Direktoren, leitende Angestellte, Mitarbeiter und Berater zu einem Preis von 0,10 Dollar pro Aktie, die am 31. Oktober 2029 auslaufen. Das Unternehmen wird außerdem 4,1 Millionen Aktien zu einem Preis von 0,10 Dollar pro Aktie ausgeben, um 408.547 Dollar an Zinsen aus wandelbaren Schuldverschreibungen zu begleichen.
- Successful raise of $1.8M through private placement
- Proceeds to advance stem cell therapeutics platform and initiate ACP sales
- Dilution of existing shareholders through issuance of 36.8M new units
- Additional dilution from 4.1M shares issued for debt interest payment
- Significant finder fees of $88,660 plus 1.7M finder options
Calgary, Alberta--(Newsfile Corp. - October 31, 2024) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed its first tranche of the private placement of units ("Units"), as announced on October 11, 2024, for gross proceeds of
If, during any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date of the Offering, the weighted average closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange ("Exchange") is greater than or equal to
In connection with the Offering, the Company paid eligible finders aggregate cash finder fees of approximately
Proceeds from the Offering are to be used to advance the Company's stem cell therapeutics platform, initiate sales and process initial batches of ACP (angiogenic cell precursors), pay finder fees, current filing and regulatory fees in connection with the Offering, and for general working capital purposes.
The Offering is subject to all necessary regulatory approvals including acceptance from the Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada.
For further details regarding the Company's Offering, please refer to the Company's News Release dated October 11, 2024. The Offering included subscribers under the investment dealer exemption. In accordance with the requirements of the investment dealer exemption, the Company confirms that there is no material fact or material change about the Company that has not been generally disclosed.
Certain directors of the Company participated in the Offering, which constitutes a "related party transaction" within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101") and the policies of the TSXV. The Company is relying upon the exemptions from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(a), respectively, of MI 61-101 on the basis that the Company is not listed on a specified stock exchange and, at the time the Offering was agreed to, neither the fair market value of the subject matter of, nor the fair market value of the consideration for, the transaction insofar as it involves an interested party (within the meaning of MI 61-101) in the Offering, exceeds
Grant of Stock Options
The Company is pleased to announce that in accordance with its stock option plan, it has granted on October 31, 2024, subject to regulatory approval, a total of 3,710,000 stock options to purchase common shares of Hemostemix (the "Options") to directors, officers, employees and consultants of Hemostemix. Of the Options granted,
Issuance of Shares for Payment of CD2 Interest
The Company, subject to regulatory approval, will issue 4,085,461 shares, at
About Hemostemix
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. For more information, please visit Hemostemix.com.
For further information, please contact:
Thomas Smeenk, President, CEO & Co-Founder
EM: tsmeenk@hemostemix.com
PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the financing of the Company and its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under physician order. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/228520
FAQ
How much did Hemostemix (HMTXF) raise in its first tranche private placement?
What is the exercise price and expiry of the warrants issued in Hemostemix's October 2024 private placement?